Pfizer to close Seagen acquisition after donating cancer drug rights
Pfizer Inc (NYSE:PFE) announced on Tuesday that it will donate the rights of royalties from sales of cancer drug Bavencio to the American Association for Cancer Research (AACR) in order to address ...
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
Pfizer said on Tuesday it has agreed to donate the rights of royalties from sales of cancer drug Bavencio to address concerns from U.S. antitrust regulators related to its $43-billion deal to buy S...
Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU
Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
Pfizer's latest play to make a competitor to Novo Nordisk's Ozempic has failed. This is the second failed attempt, and it might not be the last one.
Biden admin announces framework to potentially seize drug patents in bid to cut consumer costs
The Biden administration floated the possibility of seizing the patents for high-priced medications from pharmaceutical companies in a move to lower drug prices. The White House put out a fact she...
Pfizer (PFE) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pfizer (PFE) closed at $28.79, indicating a -1.03% shift from the previous trading day.
Pfizer CEO slams presidents of elite colleges over ‘despicable' antisemitism
Pfizer CEO Albert Bourla criticized the "despicable" testimony of three elite university presidents who were "hiding behind calls for 'context'" before deeming such rhetoric impermissible.
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated pat...
Pfizer's Obesity Pill Disappointed. Biotech Rivals Are Rubbing Their Hands.
Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.
Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024
Pfizer has experienced a total return loss of nearly -40% so far in 2023, largely due to downshifts in demand for COVID-19 vaccines and antiviral products. Shareholders faced additional challenges,...
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.
Pfizer: Between Hope, Despair, And A 5.7% Yield
Pfizer has underperformed the S&P 500, healthcare stocks, and high-yield stocks since 2013. The company's weight-loss pill has faced setbacks and is not competitive with leading drugs from other ph...
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
Before successful weight loss treatments such as Wegovy and Ozempic, the pharmaceutical path to treating obesity was strewn with failures dating back decades.
Expectations for Pfizer have been low, says Mizuho's Jared Holz on weight-loss pill setback
Jared Holz, Mizuho, joins 'Fast Money' to talk Pfizer's weight-loss pill setback.
Pfizer Shares Drop as It Ends Study of Weight-Loss Pill Due to Patient Side Effects
Pfizer (PFE) was the worst-performing stock in the S&P 500 Friday as shares dropped over 4% in early trading after the drug maker announced it was ending development of a twice-a-day weight-loss pi...
Related Companies